TransCode Therapeutics Inc (NASDAQ:RNAZ) currently has a daily average trading volume of 2.57M but it saw 1816126 shares traded in last market. With a market cap of 0.54M USD, the company’s current market price of $0.77 came rising about 1.32 while comparing to the previous closing price of $0.76. In past 52 weeks, the stock remained buoying in the range of price level as high as $66.33 and as low as $0.64. In the recent trading on the day, stock has struck highest price mark of $0.76 while lowest mark touched by it was $0.86.
Taking a look at 20-day trading activity of TransCode Therapeutics Inc (RNAZ) gives us an average price of $2.2015, while its current price level is -98.84% below from 52-week high level whereas it is 19.38% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $5.1860 while that of 200 days or SMA-200 reads an average of $13.8289. A closer look into the stock’s movement over the week reveals that its volatility is standing at 19.14% during that period while stretching the period over a month that increases to 24.70%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 26.61 which implies that the stock is in oversold territory.
Over the week, RNAZ’s stock price is moving 3.77% up while it is -92.19% when we observe its performance for the past one month. Year-to-date it is -77.15% down and over the past year, the stock is showing a downside performance of -96.55%.
The company is expected to be releasing its next quarterly report on 2024-Nov-13, for which analysts forecasted an EPS of -3.21 while estimate for next year EPS is -4.76. Moreover, analysts are in estimates of $300k for current-quarter revenue.
Currently, TransCode Therapeutics Inc’s total number of outstanding shares is 0.70M with 0.01% of that held by the insiders while 22.36% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -903.45% and return on equity (ROE) at -490.03%. Stock’s beta reads 1.40. Stock has a price to book (P/B) ratio of 0.24. Its return on asset (ROA) is -210.77% on average.
